Introduction: Xi'an Antai Pharmaceutical Co., Ltd. was established in 1992 and is located in the West District of Xi'an High-tech Industrial Development Zone, the ancient capital, with a total investment of 40 million yuan. The company has a 5,600-square-meter production and scientific research building and a 750-square-meter modern office building built in strict accordance with GMP standards to develop, research, and sell Chinese and Western medicines, preparations, pharmaceutical raw material intermediates, new special drugs, biological preparations, and health care products. and medical equipment. The annual production capacity is 1 billion tablets, 50 million injections, 50 tons of granules, and 75 million capsules, with an annual output value of 100 million yuan. Antai Pharmaceutical's current leading products include: "Weierben" injection, an injection for the treatment of chronic bronchitis, asthma and other respiratory diseases; a new generation of broad-spectrum and highly effective oral antibacterial drug roxithromycin capsules; and national Class III novel viral Myocarditis treatment drug Huodan tablets; "Sucralfate special-shaped chewable tablets" mainly used to treat peptic ulcer; anti-inflammatory analgesic "Mefenamic acid capsules", etc. The company all uses the most advanced equipment in the country: production is equipped with high-speed mixers, semi-automatic 35mm tablet punching machines, program-controlled spray coating devices, aluminum-plastic packaging machines, water needle washing, drying and filling sealing machines, fully automatic double-door sterilization cabinets, It has the country's highest-level production equipment such as water needle photoelectric foreign matter inspection machines and multi-effect distillation machines; it also has electronic balances, UV spectrophotometers, high-pressure liquid chromatographs, intelligent release meters, thin-layer scanners and other detection methods. In April 1998, the company's board of directors made major adjustments to the original company's leadership team. The board of directors hired Gui Xiaodong, who had extensive experience in pharmaceutical enterprise management, as general manager, formed a new leadership team, enriched market management capabilities, and The company's future work has put forward higher requirements. In terms of market, the company has established a medical department and an after-sales service department in line with the policy of "customers first" and "market first". In terms of market layout, company leaders have visited more than ten provinces in the past few months, including Guangdong, Hainan, Hunan, Jiangxi, Gansu, Ningxia, Qinghai, Liaoning, Tianjin, Shanxi, Jiangsu, Zhejiang, Beijing, Hebei, Henan, Inner Mongolia, etc. Municipalities and autonomous regions have made strategic adjustments to the original market layout, strengthened regional management, and initially formed a market management network centered on Xi'an.
Legal representative: Li Hongxuan
Establishment date: 1992-12-30
Registered capital: RMB 20,019,087
Industrial and commercial registration number : 610100400001688
Enterprise type: Limited liability company (natural person investment or holding)
Company address: No. 21, Gaoxin 1st Road, High-tech Zone, Xi'an